Serological response 5 months after the BNT162b2 COVID-19 vaccination in patients with various hematological disorders in Japan
CONCLUSION: Our study shows that patients with hematological disorders are at risk of developing severe COVID-19 infections because of low responsiveness to vaccination. Moreover, the rate of antibody positivity differed between the disease groups. Further studies are warranted to determine an appropriate preventive method for these patients, especially those with B-NHL.PMID:38025915 | PMC:PMC10655153 | DOI:10.7774/cevr.2023.12.4.319 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 29, 2023 Category: Cancer & Oncology Authors: Yoshiaki Marumo Takashi Yoshida Yuki Furukawa Kenji Ina Ayumi Kamiya Takae Kataoka Satoshi Kayukawa Source Type: research

REAP-2: An interactive quantitative tool for robust and efficient dose-response curve estimation
J Clin Transl Sci. 2023 Oct 13;7(1):e219. doi: 10.1017/cts.2023.642. eCollection 2023.ABSTRACTREAP-2 is an interactive dose-response curve estimation tool for Robust and Efficient Assessment of drug Potency. It provides user-friendly dose-response curve estimation for in vitro studies and conducts statistical testing for model comparisons with a redesigned user interface. We also make a major update of the underlying estimation method with penalized beta regression, which demonstrates great reliability and accuracy in dose estimation and uncertainty quantification. In this note, we describe the method and implementation of...
Source: Clinical Lymphoma and Myeloma - November 29, 2023 Category: Cancer & Oncology Authors: Xinying Fang Xinyi Liu Vernon M Chinchilli Michael Wang Hong-Gang Wang Nikolay V Dokholyan Chan Shen J Jack Lee Shouhao Zhou Source Type: research

EZH2 K63-polyubiquitination affecting migration in extranodal natural killer/T-cell lymphoma
CONCLUSIONS: Altogether, TRIP12 induces K63-linked site-specific polyubiquitination of EZH2 for stabilization, which promotes ENKTL cell migration and could be targeted by dexamethasone treatment.PMID:38031139 | DOI:10.1186/s13148-023-01606-6 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 29, 2023 Category: Cancer & Oncology Authors: Boheng Li Qidi Zhou Qin Wan Xuan Qiao Shangying Chen Jianbiao Zhou Zhijun Wuxiao Lei Luo Siok-Bian Ng Jieping Li Wee-Joo Chng Source Type: research

Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma
CONCLUSION: Our findings suggest that optimizing FA dosing to avoid very high rescue doses may improve treatment outcomes in PCNSL patients receiving HDMTX. Further prospective studies are warranted to validate these findings.PMID:38008594 | DOI:10.1016/j.clml.2023.10.012 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 26, 2023 Category: Cancer & Oncology Authors: Arnon Haran Noa Gross Even-Zohar Michal Haran Eyal Lebel Shlomzion Aumann Adir Shaulov Moshe Gatt Boaz Nachmias Source Type: research

Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma
CONCLUSION: Our findings suggest that optimizing FA dosing to avoid very high rescue doses may improve treatment outcomes in PCNSL patients receiving HDMTX. Further prospective studies are warranted to validate these findings.PMID:38008594 | DOI:10.1016/j.clml.2023.10.012 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 26, 2023 Category: Cancer & Oncology Authors: Arnon Haran Noa Gross Even-Zohar Michal Haran Eyal Lebel Shlomzion Aumann Adir Shaulov Moshe Gatt Boaz Nachmias Source Type: research

SOHO State of the Art Updates and Next Questions: Understanding and Overcoming Venetoclax Resistance in Hematologic Malignancies
Clin Lymphoma Myeloma Leuk. 2023 Oct 21:S2152-2650(23)02150-X. doi: 10.1016/j.clml.2023.10.006. Online ahead of print.ABSTRACTThe discovery of Venetoclax (VEN) has transformed the therapeutic landscape of acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). However, the response is heterogeneous with 10% to 50% of newly diagnosed AML patients not responding to hypomethylating agent (HMA) and VEN. Furthermore, up to 40% of responding patients relapse shortly. This review discusses the mechanism of action of Venetoclax and the major mechanisms of inherent and acquired resistance to VEN. VEN is highly specific...
Source: Clinical Lymphoma and Myeloma - November 25, 2023 Category: Cancer & Oncology Authors: Mark Forsberg Marina Konopleva Source Type: research

Survival Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma Treated With Radiation Therapy
CONCLUSION: Though there is no consensus on optimal treatment indications for RT in LS-DLBCL, these data suggest certain subgroups may have benefit when RT is added to front-line chemotherapy.PMID:38000981 | DOI:10.1016/j.clml.2023.09.006 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 24, 2023 Category: Cancer & Oncology Authors: Daniel A Ermann Victoria A Vardell Harsh Shah Lindsey Fitzgerald Randa Tao David K Gaffney Deborah M Stephens Boyu Hu Source Type: research

Survival Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma Treated With Radiation Therapy
CONCLUSION: Though there is no consensus on optimal treatment indications for RT in LS-DLBCL, these data suggest certain subgroups may have benefit when RT is added to front-line chemotherapy.PMID:38000981 | DOI:10.1016/j.clml.2023.09.006 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 24, 2023 Category: Cancer & Oncology Authors: Daniel A Ermann Victoria A Vardell Harsh Shah Lindsey Fitzgerald Randa Tao David K Gaffney Deborah M Stephens Boyu Hu Source Type: research

Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs)
CONCLUSION: Median OS with both HMAs remained significantly shorter than in the AZA-001 clinical trial, highlighting how patient outcomes vary between clinical and real-world settings. Further research is required to understand why these disparities exist.PMID:37996264 | DOI:10.1016/j.clml.2023.10.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 23, 2023 Category: Cancer & Oncology Authors: Amer M Zeidan Elizabeth S Mearns Carmen D Ng Anuj Shah Neil Lamarre Archibong Yellow-Duke Neda Alrawashdh Baiyu Yang Wei-Han Cheng Cat N Bui Anders Svensson Source Type: research

Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting
CONCLUSION: This study supports ixazomib-based therapy as an effective and tolerable treatment in the real-world. Outcomes were favorable in patients with 1 or ≥ 2 prior lines of therapy who were not lenalidomide- or PI-refractory.PMID:37996265 | DOI:10.1016/j.clml.2023.10.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 23, 2023 Category: Cancer & Oncology Authors: Heinz Ludwig Karthik Ramasamy Mar ía-Victoria Mateos Bhuvan Kishore Varga Gergely Miriam Ladicka Alessandra Ori Lucia Simoni Nawal Bent-Ennakhil Dawn Marie Stull Fran çois Gavini Evangelos Terpos Roman H ájek Source Type: research

Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs)
CONCLUSION: Median OS with both HMAs remained significantly shorter than in the AZA-001 clinical trial, highlighting how patient outcomes vary between clinical and real-world settings. Further research is required to understand why these disparities exist.PMID:37996264 | DOI:10.1016/j.clml.2023.10.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 23, 2023 Category: Cancer & Oncology Authors: Amer M Zeidan Elizabeth S Mearns Carmen D Ng Anuj Shah Neil Lamarre Archibong Yellow-Duke Neda Alrawashdh Baiyu Yang Wei-Han Cheng Cat N Bui Anders Svensson Source Type: research

Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting
CONCLUSION: This study supports ixazomib-based therapy as an effective and tolerable treatment in the real-world. Outcomes were favorable in patients with 1 or ≥ 2 prior lines of therapy who were not lenalidomide- or PI-refractory.PMID:37996265 | DOI:10.1016/j.clml.2023.10.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 23, 2023 Category: Cancer & Oncology Authors: Heinz Ludwig Karthik Ramasamy Mar ía-Victoria Mateos Bhuvan Kishore Varga Gergely Miriam Ladicka Alessandra Ori Lucia Simoni Nawal Bent-Ennakhil Dawn Marie Stull Fran çois Gavini Evangelos Terpos Roman H ájek Source Type: research

Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma
CONCLUSIONS: ITCs suggest that mosunetuzumab may lead to superior outcomes over tazemetostat (in EHZ2wild-type patients) and PI3K inhibitors and may be a promising alternative to re-challenging with a different anti-CD20 regimen in patients who relapse after ≥2 prior anti-CD20 lines. Although preliminary results somewhat favored CART therapies, limitations and uncertainties remain because of intrinsic differences in study design. Mosunetuzumab could thus be a promising treatment option for patients with RR FL after ≥2 prior therapies.PMID:37981564 | DOI:10.1016/j.clml.2023.09.007 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 19, 2023 Category: Cancer & Oncology Authors: Francesc Bosch John Kuruvilla Theodoros P Vassilakopoulos Danilo Di Maio Michael C Wei Marie-Helene Blanchet Zumofen Loretta J Nastoupil Source Type: research

Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma
CONCLUSIONS: ITCs suggest that mosunetuzumab may lead to superior outcomes over tazemetostat (in EHZ2wild-type patients) and PI3K inhibitors and may be a promising alternative to re-challenging with a different anti-CD20 regimen in patients who relapse after ≥2 prior anti-CD20 lines. Although preliminary results somewhat favored CART therapies, limitations and uncertainties remain because of intrinsic differences in study design. Mosunetuzumab could thus be a promising treatment option for patients with RR FL after ≥2 prior therapies.PMID:37981564 | DOI:10.1016/j.clml.2023.09.007 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 19, 2023 Category: Cancer & Oncology Authors: Francesc Bosch John Kuruvilla Theodoros P Vassilakopoulos Danilo Di Maio Michael C Wei Marie-Helene Blanchet Zumofen Loretta J Nastoupil Source Type: research

Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma
CONCLUSIONS: ITCs suggest that mosunetuzumab may lead to superior outcomes over tazemetostat (in EHZ2wild-type patients) and PI3K inhibitors and may be a promising alternative to re-challenging with a different anti-CD20 regimen in patients who relapse after ≥2 prior anti-CD20 lines. Although preliminary results somewhat favored CART therapies, limitations and uncertainties remain because of intrinsic differences in study design. Mosunetuzumab could thus be a promising treatment option for patients with RR FL after ≥2 prior therapies.PMID:37981564 | DOI:10.1016/j.clml.2023.09.007 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - November 19, 2023 Category: Cancer & Oncology Authors: Francesc Bosch John Kuruvilla Theodoros P Vassilakopoulos Danilo Di Maio Michael C Wei Marie-Helene Blanchet Zumofen Loretta J Nastoupil Source Type: research